GlassScriptPhysician profile
Travis R Berger
NPI 1275060998
$6,859.75
in general payments reported to CMS, 2019-2025
41 companies · $1,199 in 2025
The $1,199 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $80.07 · 2021: $1,116 · 2022: $1,429 · 2023: $1,664 · 2024: $1,371 · 2025: $1,199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,234.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,234.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,279.47 | 2020-2025 | Qulipta, Ubrelvy, Linzess |
| Novo Nordisk INC | $1,038.96 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $766.42 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $368.27 | 2021-2025 | Evenity, Prolia, Repatha |
| Lilly USA, LLC | $336.94 | 2021-2025 | Mounjaro, Zepbound, Emgality |
| Astrazeneca Pharmaceuticals LP | $324.35 | 2020-2025 | Farxiga, Breztri, Fasenra |
| Pfizer INC. | $252.51 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $229.86 | 2021-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Sanofi-Aventis U.S. LLC | $183.29 | 2021-2023 | |
| Otsuka America Pharmaceutical, INC. | $178.83 | 2022-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $164.39 | 2021-2022 | |
| Amarin Pharma, INC. | $146.15 | 2020-2022 | |
| Astellas Pharma US INC | $143.78 | 2022-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $128.00 | 2022-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $110.03 | 2021-2023 | Vaxneuvance, Gardasil 9, Proquad |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.78 | 2021-2025 | Jardiance, Synjardy, Trijardy Xr |
| E.R. Squibb & Sons, L.L.C. | $100.94 | 2022-2025 | Eliquis, Camzyos |
| Dexcom, INC. | $91.31 | 2021-2023 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $80.91 | 2024-2025 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $76.34 | 2021-2025 | Xifaxan |
| Biohaven Pharmaceuticals, INC. | $70.79 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $70.48 | 2022 | |
| Exact Sciences Corporation | $64.74 | 2023-2025 | Cologuard Collection Kit |
| Ibsa Pharma INC. | $63.42 | 2023-2024 | Tirosint, Licart, Licart |
| Kowa Pharmaceuticals America, INC. | $59.46 | 2021-2024 | Zoryve |
| Cequr Corporation | $54.68 | 2023-2025 | Cequr Simplicity |
| Sanofi Pasteur INC. | $43.52 | 2023-2025 | |
| Axsome Therapeutics, INC. | $38.21 | 2024 | Auvelity |
| Genentech USA, INC. | $31.13 | 2020-2022 | |
| Phathom Pharmaceuticals, INC. | $29.86 | 2024 | Voquezna |
| Sunovion Pharmaceuticals INC. | $27.11 | 2021-2022 | |
| Impel Pharmaceuticals INC. | $24.50 | 2022 | |
| Eisai INC. | $24.38 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.76 | 2024 | Caplyta |
| Clarus Therapeutics INC. | $23.29 | 2021 | |
| Boston Scientific Corporation | $22.85 | 2024 | Wavewriter Alpha Prime 16 |
| Bayer Healthcare Pharmaceuticals INC. | $18.86 | 2022 | |
| Ironwood Pharmaceuticals, INC | $18.10 | 2024 | |
| Medtronic, INC. | $14.53 | 2023 | Inpen Smart Insulin Delivery System |
| Lundbeck LLC | $13.47 | 2023 | Rexulti |
| Tolmar, INC. | $13.08 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Travis Berger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.